DOI: 10.6084/m9.figshare.28303733.v1
title: Supplementary materials: Budget impact analyses of hemoglobin A1c and lipid panel point-of-care testing with Afinion™ 2 in Canada and Italy

description: <b>These are peer-reviewed supplementary materials for the article</b><b> </b><b>'</b><b>Budget impact analyses of hemoglobin A1c </b><b>and lipid panel point-of-care testing with </b><b>Afinion™ 2 in Canada and Italy</b><b>'</b><b> </b><b>published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Supplementary Table 1: </b>Market Shares<b>Supplementary Table 2: </b>Patient Flow Subcategorization of Monitoring Patients with Diagnosed Diabetes or Dyslipidemia<b>Supplementary Table 3: </b>Afinion™ 2 POC Device Costs and PCP Practice Parameters<b>Supplementary Table 4: </b>HbA1c POC Healthcare Resource Use Costs in the Monitoring Population<b>Supplementary Table 5: </b>Lipid Panel POC Healthcare Resource Use Costs in the Monitoring Population<b>Supplementary Table 6: </b>Indirect Costs in the Monitoring Population<b>Appendix A</b><b>Supplementary Table 7: </b>Indirect Costs in the Screening Population<b>Supplementary Table 8: </b>Scenario Analyses: Incremental Budget Impact of Afinion™ 2 POC HbA1c Testing – Canada<b>Supplementary Table 9: </b>Scenario Analyses: Incremental Budget Impact of Afinion™ 2 POC HbA1c Testing<b>Appendix B</b><b>Supplementary Table 10: </b>Scenario Analyses: Incremental Budget Impact of Afinion™ 2 POC Lipid Panel Testing – Canada – Italy<b>Supplementary Table 11: </b>Scenario Analyses: Incremental Budget Impact of Afinion™ 2 POC Lipid Panel Testing – Italy Baseline (2024) Year<b>References</b><b>Abstract</b><br><b>Aim:</b> Screening and monitoring of diabetes or dyslipidemia frequently involves a multi-step processrequiring patients to obtain test requisitions from their primary care physician (PCP), followed by a laboratory visit and re-consultation. Point-of-care testing (POCT) for hemoglobin A1c (HbA1c) and lipid panel can streamline the patient care pathway. This study assessed the budget impact of introducing Afinion™ 2 POCT (Abbot Rapid Diagnostics) from the Canadian and Italian societal perspectives. <b>Methods: </b>Budget impact models were developed for Canada and Italy over a 5-year time horizon (2025 to 2029). The analyses considered the screening and monitoring of diabetes or dyslipidemia for patients utilizing the public healthcare system and attending primary care, and included direct costs (testing, consultations) and indirect costs (productivity loss, transportation) based on published sources. The budget impact (BI) was calculated by comparing scenarios with and without POCT. All costs were adjusted to Canadian dollars ($) or 2024 Euros (€). Scenario analyses were conducted to explore the impact of alternative assumptions. <b>Results:</b> The 5-year cumulative BI was -$758,006,692 (-$50,709,964 direct, -$707,296,728 indirect) for HbA1c POCT and -$726,452,755 ($2,684,011 direct, -$729,136,766 indirect) for lipid panel POCT in Canada and -€1,380,658,764 (-€6,391,954 direct, -€1,374,266,809 indirect) for HbA1c POCT and -€851,792,115 (€55,962,879 direct, -€907,754,993 indirect) for lipid panel POCT in Italy. In both countries, cost savings for both the healthcare payer and patients were observed for HbA1c POCT, while costs savings were derived from patient indirect costs for lipid panel POCT. The analyses estimated that 1,558,062 and 1,501,260 PCP consultations in Canada, 4,962,338 and 1,951,026 PCP consultations in Italy were avoided with implementation of POCT for HbA1c and lipid panel, respectively. Scenario analyses demonstrated potential further cost savings with implementation of POCT in pharmacies. <b>Conclusion:</b> This study demonstrates that the adoption of Afinion 2 POCT for HbA1c and lipid panel can provide efficiencies to different types of healthcare systems through reducing PCP consultations, saving time and money for patients and providing cost savings for payers.